We have isolated a high-affinity HLA-A2-restricted TCR against the HPV-16 E6 oncoprotein. This was accomplished by identifying from the metastatic tumor of a patient with anal cancer a T cell clone against the E6 29-38. The gene sequence of the TCR expressed by this clone was determined, and a retroviral expression vector encoding the TCR was generated. T cells transduced to express this TCR display high-avidity for the HPV-16 E6 29-38 epitope as well as specific recognition of HPV-16-positive tumor lines. A clinical trial testing adoptive transfer of autologous T cells transduced to express this TCR for the treatment of HPV-positive cancers has been completed. Data analysis is underway. In addition, we have identified a TCR targeting HPV-16 E7. A clinical trial of this TCR is also active.
| Hinrichs, Christian S (2018) Cell-based molecularly targeted therapy: targeting oncoproteins with T cell receptor gene therapy. J Clin Invest 128:1261-1263 |
| Hinrichs, Christian S (2016) Molecular Pathways: Breaking the Epithelial Cancer Barrier for Chimeric Antigen Receptor and T-cell Receptor Gene Therapy. Clin Cancer Res 22:1559-64 |
| Draper, Lindsey M; Kwong, Mei Li M; Gros, Alena et al. (2015) Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6. Clin Cancer Res 21:4431-9 |
| Hinrichs, Christian S; Rosenberg, Steven A (2014) Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev 257:56-71 |
| Hinrichs, Christian S; Restifo, Nicholas P (2013) Reassessing target antigens for adoptive T-cell therapy. Nat Biotechnol 31:999-1008 |
